Clinical Trial Plan Approved for 'Riporaksel-aek' Phase 3 Breast Cancer Study in Serbia by Daehwaje-yak

[Asia Economy Reporter Oh Ju-yeon] Daehwa Pharmaceutical announced on the 5th that it has received approval for the Phase 3 clinical trial plan (IND) of 'Liporaxel Solution' for breast cancer in Serbia. The company stated, "To expedite the global market entry of Liporaxel Solution, we have expanded the multinational clinical trial with breast cancer as the indication, following Korea and China, to include three Eastern European countries (Hungary, Bulgaria, Serbia) as participating countries. We plan to recruit clinical patients at about 20 hospitals across the three Eastern European countries, aiming to enroll the first patient within this year."

This content was produced with the assistance of AI translation services.